Spero Therapeutics Inc (SPRO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.21-0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPRO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.8% |
| Our one-year growth estimate | diamond | -89.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 33.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SPRO — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-07-14
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under “Royalty Financing Agreements” in
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Spero's performance.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Updates on cash runway are important for Spero's financial health. This affects how they operate.
Watch forSpero confirms cash runway into the second half of 2029 with the recent financing.
Also watch forSpero changes cash runway guidance to show possible funding problems.
Why it matters: Utebzi brings in money for Spero. This is important after FDA approval.
Supportive ifUtebzi will start generating revenue after its launch, expected by the end of 2026.
Worry ifUtebzi launch is delayed or fails to generate expected revenue.
Why it matters: FDA approval would confirm the potential of tebipenem HBr as a new treatment for cUTIs. This could boost Spero's market position.
Supportive ifThe FDA approves tebipenem HBr for complicated urinary tract infections. This is by June 18, 2026.
Worry ifFDA denies approval or delays the decision beyond the PDUFA date.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $568 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,141 loss on $10,000 · 61.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on tebipenem HBr could show progress in sales and market acceptance. This is key for growth.
Supportive ifLook for a press release about new partnerships or sales for tebipenem HBr.
Worry ifWatch for no news or problems in selling tebipenem HBr.
Why it matters: Updates on Utebzi's launch may show if Spero can make money. This is key for stability.
Supportive ifSpero shares the launch timeline for Utebzi after FDA approval by the end of 2026.
Worry ifThere are no updates on Utebzi's launch or any delays.
Why it matters: Starting the Phase 2 trial is key to advancing SP001. This could lead to new treatment options for patients with IgG4-related disease.
Supportive ifSpero confirms the Phase 2 trial for SP001 begins in Q2 2027.
Worry ifDelay in starting the Phase 2 trial beyond Q2 2027.
Why it matters: Utebzi's launch is crucial for revenue growth. It is the first oral carbapenem antibiotic for cUTIs.
Supportive ifUtebzi becomes available to U.S. patients by the end of 2026 as planned.
Worry ifUtebzi's launch is delayed beyond 2026.
Why it matters: Updates on cash runway will show if Spero can fund operations through 2029. This affects their ability to advance programs.
Supportive ifManagement confirms cash runway extends into the second half of 2029.
Worry ifManagement says cash will last less time than they thought.
Why it matters: News on the Innovent deal could show progress in SP001's development.
Watch forSpero shares news on milestones or payments from the Innovent deal.
Also watch forNo news or delays in the Innovent deal's milestones.